Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Neoplasms × belzutifan × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Renal Cell 21 Kidney Neoplasms 8 Parkinson Disease 4, Autosomal Dominant Lewy Body 5 von Hippel-Lindau Disease 4 Pheochromocytoma 2 Paraganglioma 2 Neoplasm Metastasis 2 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Recurrence 1 Ovarian Neoplasms 1 Neuroectodermal Tumors, Primitive 1 Neoplasms 1 Metastatic Castration-Resistant Prostate Cancer 1 Hemangioblastoma 1 Glioblastoma 1 Endometrial Neoplasms 1 Clear-cell metastatic renal cell carcinoma 1 Carcinoma 1 Breast Neoplasms 1 Adenoma, Islet Cell 1

Interventions

pembrolizumab 146 Gemcitabine 134 Paclitaxel 126 Carboplatin 116 Bevacizumab 108 Docetaxel 94 Cyclophosphamide 93 Cisplatin 92 Exercise 78 Nivolumab 77 Fluorouracil 73 Capecitabine 72 Dexamethasone 70 Irinotecan 62 Radiotherapy 57 Pemetrexed 57 Oxaliplatin 57 Standard of Care 55 Leucovorin 53 Cetuximab 47 Drug Therapy 45 Sorafenib 44 Erlotinib Hydrochloride 44 Doxorubicin 41 atezolizumab 40 Blood Specimen Collection 40 130-nm albumin-bound paclitaxel 37 trametinib 34 Ipilimumab 34 venetoclax 32

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04976634 2025-04-06

MK-6482-016

Merck Sharp & Dohme LLC

Phase 2 Active not recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡